AgomAb Therapeutics NV

AgomAb Therapeutics is a drug development company working on treatments for inflammatory and scarring diseases. The company is testing an oral medication called Ontunisertib for Crohn's disease, an inhaled treatment for a lung scarring condition called idiopathic pulmonary fibrosis, and an antibody therapy in early development. All of these drugs are still in clinical trials and have not been approved for patients yet. The company was founded in 2017 and is based in Belgium.